Next Article in Journal
X-ray Diffraction Studies on the Structural Origin of Dynamic Tension Recovery Following Ramp-Shaped Releases in High-Ca Rigor Muscle Fibers
Previous Article in Journal
Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer
Previous Article in Special Issue
The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance
Open AccessReview

Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies

1
Department of Pharmacy-Drug Sciences, University of Bari, 70125 Bari, Italy
2
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
*
Author to whom correspondence should be addressed.
These authors equally contributed to the work.
Int. J. Mol. Sci. 2020, 21(4), 1242; https://doi.org/10.3390/ijms21041242
Received: 14 January 2020 / Revised: 8 February 2020 / Accepted: 9 February 2020 / Published: 13 February 2020
(This article belongs to the Special Issue Cisplatin in Cancer Therapy: Molecular Mechanisms of Action)
Among the severe side effects induced by cisplatin chemotherapy, muscle wasting is the most relevant one. This effect is a major cause for a clinical decline of cancer patients, since it is a negative predictor of treatment outcome and associated to increased mortality. However, despite its toxicity even at low doses, cisplatin remains the first-line therapy for several types of solid tumors. Thus, effective pharmacological treatments counteracting or minimizing cisplatin-induced muscle wasting are urgently needed. The dissection of the molecular pathways responsible for cisplatin-induced muscle dysfunction gives the possibility to identify novel promising therapeutic targets. In this context, the use of animal model of cisplatin-induced cachexia is very useful. Here, we report an update of the most relevant researches on the mechanisms underlying cisplatin-induced muscle wasting and on the most promising potential therapeutic options to preserve muscle mass and function. View Full-Text
Keywords: cisplatin; skeletal muscle; ghrelin; growth hormone secretagogues (GHS); muscle atrophy cisplatin; skeletal muscle; ghrelin; growth hormone secretagogues (GHS); muscle atrophy
Show Figures

Graphical abstract

MDPI and ACS Style

Conte, E.; Bresciani, E.; Rizzi, L.; Cappellari, O.; De Luca, A.; Torsello, A.; Liantonio, A. Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies. Int. J. Mol. Sci. 2020, 21, 1242.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop